Patents by Inventor Taku Ikenogami

Taku Ikenogami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIHYDROOXADIAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOF
    Publication number: 20240101572
    Abstract: The present invention provides a compound having a PLD inhibitory activity. The present invention provides a compound of the following structural formula, and the like, or a pharmaceutically acceptable salt thereof. wherein each symbol is as defined in the description.
    Type: Application
    Filed: June 15, 2023
    Publication date: March 28, 2024
    Inventors: Masahiro YOKOTA, Tetsudo KAYA, Makoto TORIZUKA, Yasuaki NAKAYAMA, Taku IKENOGAMI, Katsuya MAEDA, Kazuki OTAKE, Kentaro SAKURAI
  • DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF
    Publication number: 20230373932
    Abstract: A compound of Formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is defined as in the specification.
    Type: Application
    Filed: December 20, 2022
    Publication date: November 23, 2023
    Inventors: Masahiro YOKOTA, Taku IKENOGAMI, Eiichi WATANABE, Noriyoshi SEKI, Takayuki SAKAI, Shingo FUJIOKA, Makoto SHIOZAKI, Katsunori SUWA, Yosuke OGOSHI, Masato NOGUCHI, Katsuya MAEDA
  • 4-METHYLDIHYDROPYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF
    Publication number: 20210363110
    Abstract: The present invention relates to 4-methyldihydropyrimidinone compounds, or pharmaceutically acceptable salts thereof, having ROR? antagonist activity, pharmaceutical compositions comprising the same, and pharmaceutical use thereof. A compound of Formula (1) or (2) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and pharmaceutical use thereof are provided.
    Type: Application
    Filed: December 18, 2020
    Publication date: November 25, 2021
    Inventors: Takayuki Sakai, Taku Ikenogami
  • DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF
    Publication number: 20210130300
    Abstract: A compound of Formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is defined as in the specification.
    Type: Application
    Filed: June 16, 2020
    Publication date: May 6, 2021
    Inventors: Masahiro YOKOTA, Taku IKENOGAMI, Eiichi WATANABE, Noriyoshi SEKI, Takayuki SAKAI, Shingo FUJIOKA, Makoto SHIOZAKI, Katsunori SUWA, Yosuke OGOSHI, Masato NOGUCHI, Katsuya MAEDA
  • 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
    Patent number: 10899717
    Abstract: The present invention relates to 4-methyldihydropyrimidinone compounds, or pharmaceutically acceptable salts thereof, having ROR? antagonist activity, pharmaceutical compositions comprising the same, and pharmaceutical use thereof. A compound of Formula (1) or (2) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and pharmaceutical use thereof are provided.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: January 26, 2021
    Assignee: JAPAN TOBACCO INC.
    Inventors: Takayuki Sakai, Taku Ikenogami
  • DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF
    Publication number: 20190359575
    Abstract: A compound of Formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is defined as in the specification.
    Type: Application
    Filed: December 20, 2018
    Publication date: November 28, 2019
    Inventors: Masahiro YOKOTA, Taku IKENOGAMI, Eiichi WATANABE, Noriyoshi SEKI, Takayuki SAKAI, Shingo FUJIOKA, Makoto SHIOZAKI, Katsunori SUWA, Yosuke OGOSHI, Masato NOGUCHI, Katsuya MAEDA
  • 4-METHYLDIHYDROPYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF
    Publication number: 20190300488
    Abstract: The present invention relates to 4-methyldihydropyrimidinone compounds, or pharmaceutically acceptable salts thereof, having ROR? antagonist activity, pharmaceutical compositions comprising the same, and pharmaceutical use thereof. A compound of Formula (1) or (2) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and pharmaceutical use thereof are provided.
    Type: Application
    Filed: February 27, 2019
    Publication date: October 3, 2019
    Inventors: Takayuki SAKAI, Taku IKENOGAMI
  • Dihydropyrimidin-2-one compounds and medical use thereof
    Patent number: 10196363
    Abstract: A compound of Formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is defined as in the specification.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 5, 2019
    Assignee: JAPAN TOBACCO INC.
    Inventors: Masahiro Yokota, Taku Ikenogami, Eiichi Watanabe, Noriyoshi Seki, Shingo Fujioka, Makoto Shiozaki, Masato Noguchi
  • DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF
    Publication number: 20160194290
    Abstract: A compound of Formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is defined as in the specification.
    Type: Application
    Filed: December 11, 2015
    Publication date: July 7, 2016
    Inventors: Masahiro YOKOTA, Taku IKENOGAMI, Eiichi WATANABE, Noriyoshi SEKI, Takayuki SAKAI, Shingo FUJIOKA, Makoto SHIOZAKI, Katsunori SUWA, Yosuke OGOSHI, Masato NOGUCHI, Katsuya MAEDA
  • TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF
    Publication number: 20160137639
    Abstract: A compound represented by Formula [I]: or pharmaceutically acceptable salt thereof, wherein each symbol is as defined in the description.
    Type: Application
    Filed: October 25, 2013
    Publication date: May 19, 2016
    Inventors: Masayuki KOTOKU, Takaki MAEBA, Noriyoshi SEKI, Shintaro HIRASHIMA, Shingo FUJIOKA, Shingo OBIKA, Hiroshi YAMANAKA, Masahiro YOKOTA, Takayuki SAKAI, Kazuyuki HIRATA, Katsuya MAEDA, Makoto SHIOZAKI, Yuko SHINAGAWA, Taku IKENOGAMI, Satoki DOI, Takahiro OKA, Takuya MATSUO, Yoshihiro SUWA, Keisuke ITO, Satoru NOJI, Yoshinori HARA
  • Azetidine compound and pharmaceutical use thereof
    Patent number: 8765739
    Abstract: Compounds of formula [I]: wherein each symbol is as defined in the description, or a pharmaceutically acceptable salts or solvates thereof.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: July 1, 2014
    Assignee: Japan Tobacco Inc.
    Inventors: Kazutaka Ikegashira, Taku Ikenogami, Naoki Ogawa, Tatsuya Matsumoto, Takahiro Oka, Takuya Matsuo, Takayuki Yamasaki
  • CaSR Antagonist
    Publication number: 20120301552
    Abstract: A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the specification. A compound having a calcium-sensing receptor antagonistic action, a pharmaceutical composition comprising the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis are provided.
    Type: Application
    Filed: December 23, 2011
    Publication date: November 29, 2012
    Applicant: JAPAN TOBACCO INC.
    Inventors: Yuko Shinagawa, Teruhiko Inoue, Toshihiro Kiguchi, Taku Ikenogami, Naoki Ogawa, Kenji Fukuda, Takashi Nakagawa, Masanori Shindo, Yuki Soejima
  • Ester derivatives and medicinal use thereof
    Patent number: 8101774
    Abstract: The present invention relates to an ester represented by the formula [1]: or its pharmaceutically acceptable salt, or use of the same. The compound represented by the formula [1] or its pharmaceutically acceptable salt is useful as an agent for the treatment or prophylaxis of hyperlipidemia or the like, since it disappears very rapidly in the living body and has an excellent MTP inhibitory activity.
    Type: Grant
    Filed: October 17, 2005
    Date of Patent: January 24, 2012
    Assignee: Japan Tobacco Inc.
    Inventors: Atsushi Hagiwara, Taku Ikenogami, Kazunori Kurihara, Toshio Taniguchi, Mitsuru Takahashi, Akio Iida
  • AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF
    Publication number: 20100331301
    Abstract: Compounds of formula [I]: wherein each symbol is as defined in the description, or a pharmaceutically acceptable salts or solvates thereof.
    Type: Application
    Filed: May 14, 2010
    Publication date: December 30, 2010
    Applicant: JAPAN TOBACCO INC.
    Inventors: Kazutaka Ikegashira, Taku Ikenogami, Naoki Ogawa, Tatsuya Matsumoto, Takahiro Oka, Takuya Matsuo, Takayuki Yamasaki
  • ESTER COMPOUND AND MEDICAL USE THEREOF
    Publication number: 20100158996
    Abstract: A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1?) (wherein R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R10)—; R3 and R4 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; R9 and R9 are each independently hydrogen atom, C1-C6 alkyl, —CON(R18) (R19) or —COO(R20), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk1 and Alk2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.
    Type: Application
    Filed: February 12, 2010
    Publication date: June 24, 2010
    Inventors: Atsushi Hagiwara, Yasuhiro Ohe, Naoya Odani, Shizue Watanabe, Taku Ikenogami, Takashi Kawai, Kenya Madono, Toshio Taniguchi
  • CaSR Antagonist
    Publication number: 20090326058
    Abstract: A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the specification. A compound having a calcium-sensing receptor antagonistic action, a pharmaceutical composition comprising the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis are provided.
    Type: Application
    Filed: March 27, 2009
    Publication date: December 31, 2009
    Applicant: JAPAN TOBACCO INC.
    Inventors: YUKO SHINAGAWA, TERUHIKO INOUE, TOSHIHIRO KIGUCHI, TAKU IKENOGAMI, NAOKI OGAWA, KENJI FUKUDA, TAKASHI NAKAGAWA, MASANORI SHINDO, YUKI SOEJIMA
  • Ester compound and medicinal use thereof
    Patent number: 7625948
    Abstract: A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1?) (wherein R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R10)—; R3 and R4 are each hydrogen atom, C1-C6alkyl or C1-C6alkoxy, etc.; R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; R8 and R9 are each independently hydrogen atom, C1-C6alkyl, —CON(R18)(R19) or —COO(R20), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk1 and Alk2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: December 1, 2009
    Assignee: Japan Tobacco Inc.
    Inventors: Atsushi Hagiwara, Yasuhiro Ohe, Naoya Odani, Shizue Watanabe, Taku Ikenogami, Takashi Kawai, Kenya Madono, Toshio Taniguchi
  • Ester compound and medicinal use thereof
    Patent number: 7538140
    Abstract: A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1?) (wherein R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R10)—; R3 and R4 are each hydrogen atom, C1-C6alkyl or C1-C6alkoxy, etc.; R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; R8 and R9 are each independently hydrogen atom, C1-C6alkyl, —CON(R18)(R19) or —COO(R20), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk1 and Alk2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: May 26, 2009
    Assignee: Japan Tobacco Inc
    Inventors: Atsushi Hagiwara, Yasuhiro Ohe, Naoya Odani, Shizue Watanabe, Taku Ikenogami, Takashi Kawai, Kenya Madono, Toshio Taniguchi
  • CaSR Antagonist
    Publication number: 20080255042
    Abstract: A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the specification. A compound having a calcium-sensing receptor antagonistic action, a pharmaceutical composition comprising the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis are provided.
    Type: Application
    Filed: August 17, 2007
    Publication date: October 16, 2008
    Applicant: JAPAN TOBACCO INC.
    Inventors: Yuko Shinagawa, Teruhiko Inoue, Toshihiro Kiguchi, Taku Ikenogami, Naoki Ogawa, Kenji Fukuda, Takashi Nakagawa, Masanori Shindo, Yuki Soejima
  • Ester derivatives and medical use thereof
    Patent number: 7432392
    Abstract: A therapeutic agent for hyperlipidemia which has no side effects on the liver unlike conventional MTP inhibitors and has excellent MTP inhibitory activity. Also, provided is an ester compound represented by the general formula (1): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 27, 2006
    Date of Patent: October 7, 2008
    Assignee: Japan Tobacco Inc.
    Inventors: Atsushi Hagiwara, Taku Ikenogami, Yasuko Mera, Yukako Sumida, Akio Iida, Toshio Taniguchi, Mitsuru Takahashi